Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Oxaliplatin regulates the autophagy of skin squamous cell carcinoma cell line through HMGB1 pathway

Lei Han , Jing Wang, Yu Xia, Jinping Maio, Juan Cao

Department of Skin, Zhangye People’s Hospital Attached to Hexi College of Gansu Province, Zhangye 734000, Gansu Province, China;

For correspondence:- Lei Han Email: zhuozhanzhong8603@163.com

Accepted: 7 October 2023 Published: 30 October 2023

Citation: Han L, Wang J, Xia Y, Maio J, Cao J. Oxaliplatin regulates the autophagy of skin squamous cell carcinoma cell line through HMGB1 pathway. Trop J Pharm Res 2023; 22(10):2053-2058 doi: 10.4314/tjpr.v22i10.5

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the influence of oxaliplatin on skin squamous cell carcinoma cell line, and the involvement of autophagy-regulating pathway of high mobility group box 1 (HMGB1) in the process.

Methods: A431 cells cultured in vitro were used. The cells were divided into groups A (treated with different concentrations of oxaliplatin) and B (treated with different concentrations of oxaliplatin combined with autophagy inhibitor 5 mmol/l3-ma). Changes in expression levels of autophagy marker molecules LC3-?, LC3-?, p62 and HMGB1 in A431 cells treated with different concentrations of oxaliplatin and different concentrations of HMGB1 were evaluated by Western blotting. Viability of A431 cells in both groups was assessed by CCK-8 assay.

Results: With increase in oxaliplatin concentration, LC3-? levels in A431 cells were up-regulated, p62 expression decreased, while autophagy level was increased significantly (p < 0.05). With increase in HMGB1 protein concentration, LC3-? level in A431 cells was raised, while p62 level was reduced, while the level of autophagy was significantly increased (p < 0.05). Oxaliplatin treatment led to significantly higher expression level of HMGB1 in the experimental group than in the control group without oxaliplatin treatment. The viability of oxaliplatin-treated group was dose-dependently and significantly lower (p < 0.05) than that of the control group. Compared with the control group, the cell viability of the 3-mA + oxaliplatin group also showed a downward trend, and the decrease was greater than that of oxaliplatin-treated group (p < 0.05).

Conclusion: Oxaliplatin upregulates autophagy by promoting HMGB1 protein expression, which may be a protective mechanism of tumor cells against oxaliplatin cytotoxicity thereby making HMGB1 protein a potential target in skin cancer therapy.

Keywords: Oxaliplatin, HMGB1, Autophagy, Skin squamous cell carcinoma